Michael Burry
Scion Asset Management
Michael Burry Regeneron Pharmaceuticals Inc stake
total: 173
Scion Asset Management REGN trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2025 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2025 Q3
According to 2025 Q3 report, Michael Burry doesn't hold any Regeneron Pharmaceuticals Inc (REGN) shares. To date, the estimated cost basis is nearly $525 for "buy" trades and estimated average "sell" price is $525. Scion Asset Management first purchased REGN in 2025 Q2, initially acquiring 15,000 shares. Since the initial investment in Regeneron Pharmaceuticals Inc (REGN), Scion Asset Management has made 1 more transaction.
When did Michael Burry sell Regeneron Pharmaceuticals Inc (REGN)?
Michael Burry sold off the entire Regeneron Pharmaceuticals Inc (REGN) position in 2025 Q3.
When did Michael Burry buy Regeneron Pharmaceuticals Inc (REGN)?
Michael Burry first invested in Regeneron Pharmaceuticals Inc (REGN) in 2025 Q2 at the reported quarter-end price of $525.00 per share.
What's the cost basis of Scion Asset Management's REGN stake?
The estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) stake is around $525.00 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $525.00
- Weighted AVG sell price:
- $525.00
Michael Burry's historical trades in Regeneron Pharmaceuticals Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
0.00%
|
0
|
$525.00
|
|
-100% (-15,000)
|
-14%
|
|
2025 Q2
|
14.00%
|
15,000
|
$525.00
|
$7,875,000
|
new
|
+14%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.